Fig. 3 | Nature Communications

Fig. 3

From: T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

Fig. 3

PD-1-targeting nanoparticles bind to T cells in vitro and in vivo. a CD8+ OT-I T cells were activated with ovalbumin-expressing B16 (ratio 1:10 B16 to T cell) for 48 h and incubated with DiD-loaded, PD-1-targeting nanoparticles for 30 min before detection of DiD by flow cytometry. Mass of polymer indicated is per 250,000 T cells. b C57BL/6 mice were inoculated subcutaneously with ovalbumin-expressing B16 melanoma cells. Once tumors reached ~400 mm3 in volume, DiD-loaded, PD-1-targeting or isotype control nanoparticles were injected intravenously. 1 h later, tumors were recovered. Flow cytometry was performed (gating shown at left), and the percentage of T cells that were positive for both PD-1 expression and nanoparticle binding was quantified (right panel); n = 5 (*p < 0.05, Two-tailed Student’s t-test)

Back to article page